



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 382 990  
A1**

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 89400428.2

(51) Int. Cl.<sup>5</sup>: **C12N 15/32, A01N 63/00**

(22) Date of filing: 15.02.89

(43) Date of publication of application:  
22.08.90 Bulletin 90/34

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

(71) Applicant: **PLANT GENETIC SYSTEMS, N.V.**  
**Kolonel Bourgstraat 106 Bus 1**  
**B-1040 Brussel(BE)**

(72) Inventor: **Peferoen, Marnix**  
**J.P. Minckelersstraat 129**  
**B-3000 Leuven(BE)**  
Inventor: **Lambert, Bart**  
**Zuidveldstraat 1**  
**B-8030 Beernem(BE)**  
Inventor: **Joos, Henk**  
**Oostmolen Zuid 5**  
**B-9880 Aalter(BE)**

(74) Representative: **Gutmann, Ernest et al**  
**S.C. Ernest Gutmann - Yves Plasseraud 67,**  
**boulevard Haussmann**  
**F-75008 Paris(FR)**

(54) **Strains of bacillus thuringiensis.**

(57) Two new Bacillus thuringiensis strains, which are deposited at the DSM under accession nos. 5131 and 5132, produce crystal proteins during sporulation that are toxic to Coleoptera. The crystal proteins contain 74 kDa and 129 kDa protoxins, respectively, which can yield 67 and 66 kDa toxins, respectively, as trypsin-digestion products. A plant, the genome of which is transformed with a DNA sequence that comes from either one of the strains and that codes for its respective toxin, is resistant to Coleoptera. Each strain, itself, or its crystals, crystal proteins, protoxin or toxin can be used as the active ingredient in an insecticidal composition for combatting Coleoptera.

**EP 0 382 990 A1**

## NEW STRAINS OF BACILLUS THURINGIENSIS

This invention relates to two new strains of *B. thuringiensis* (the "BtPGSI208 strain" and the "BtPGSI245 strain"), each of which produces crystallized proteins (the "BtPGSI208 crystal proteins" and the "BtPGSI245 crystal proteins", respectively) which are packaged in crystals (the "BtPGSI208 crystals" and the "BtPGSI245 crystals", respectively) during sporulation. The BtPGSI208 and BtPGSI245 strains were deposited under the provisions of the Budapest Treaty at the Deutsche Sammlung Für Mikroorganismen and Zellkulturen ("DSM"), Mascheroder Weg 1B, D-3300 Braunschweig, Federal Republic of Germany, under accession numbers 5131 and 5132, respectively, on January 19, 1989.

This invention also relates to an insecticide composition that is active against Coleoptera and that comprises the BtPGSI208 or BtPGSI245 strain, as such, or preferably the BtPGSI208 or BtPGSI245 crystals, crystal proteins or the active component(s) thereof as an active ingredient.

This invention further relates to:

1) a DNA sequence (the "btPGSI208 gene"), from the genome of the BtPGSI208 strain, which encodes a 74 kDa protein (the "BtPGSI208 protoxin") that is found in the BtPGSI208 crystals; and

2) A DNA sequence (the "btPGSI245 gene"), from the genome of the BtPGSI245 strain, which encodes a 129 kDa protein (the "BtPGSI245 protoxin") that is found in the BtPGSI245 crystals. The BtPGSI208 and BtPGSI245 protoxins are the proteins that are produced by their respective BtPGSI208 and BtPGSI245 strains before being packaged into their respective BtPGSI208 and BtPGSI245 crystals.

This invention still further relates to a 67 kDa protein ("the BtPGSI208 toxin") and a 66 kDa protein (the "BtPGSI245 toxin") which can be obtained from the BtPGSI208 protoxin and the BtPGSI245 protoxin, respectively. The BtPGSI208 and BtPGSI245 toxins are insecticidally active proteins which can be liberated from the BtPGSI208 crystals and the BtPGSI245 crystals, respectively, produced by the BtPGSI208 strain and the BtPGSI245 strain, respectively, and each toxin has a high activity against Coleoptera. The BtPGSI208 and BtPGSI245 toxins are believed to represent the smallest portions of their respective BtPGSI208 and BtPGSI245 protoxins which are insecticidally effective against Coleoptera.

This invention yet further relates to a chimaeric gene that can be used to transform a plant cell and that contains:

1) a part of the btPGSI208 or btPGSI245 gene (the "insecticidally effective btPGSI208 or btPGSI245 gene part") encoding an insecticidally effective portion of the respective BtPGSI208 or BtPGSI245 protoxin, preferably a truncated part of the btPGSI208 or btPGSI245 gene (the "truncated btPGSI208 or btPGSI245 gene") encoding just the respective BtPGSI208 or BtPGSI245 toxin;

2) a promoter suitable for transcription of the insecticidally effective btPGSI208 or btPGSI245 gene part in a plant cell; and

3) suitable transcription termination and polyadenylation signals for expressing the insecticidally effective btPGSI208 or btPGSI245 gene part in a plant cell. This chimaeric gene is hereinafter generally referred to as the "btPGSI208 or btPGSI245 chimaeric gene." Preferably, the insecticidally effective btPGSI208 or btPGSI245 gene part is present in the btPGSI208 or btPGSI245 chimaeric gene as a hybrid gene comprising a fusion of the truncated btPGSI208 or btPGSI245 gene and a selectable marker gene, such as the neo gene (the "btPGSI208-neo or btPGSI245-neo hybrid gene").

This invention also relates to:

1) a cell (the "transformed plant cell") of a plant, such as potato, the genome of which is transformed with the insecticidally effective btPGSI208 or btPGSI245 gene part; and

2) a plant (the "transformed plant") which is regenerated from the transformed plant cell or is produced from the so-regenerated plant, the genome of which contains the insecticidally effective btPGSI208 or btPGSI245 gene part and which is resistant to Coleoptera.

### Background of the Invention

*B. thuringiensis* ("Bt") is a gram-positive bacterium which produces endogenous crystals upon sporulation. The crystals are composed of proteins which are specifically toxic against insect larvae. Three different Bt pathotypes have been described: pathotype A that is active against Lepidoptera, e.g., caterpillars; pathotype B that is active against certain Diptera, e.g., mosquitos and black flies; and pathotype C that is active against Coleoptera, e.g., beetles (Ellar et al, 1986).

A Bt strain, whose crystals are toxic to Coleoptera, has been described as Bt tenebrionis (US patent 4,766,203; European patent publication 0,149,162), Bt M-7 or Bt San Diego (European patent publication

0,213,818; U.S. patent 4,771,131) and BtS1 (European patent application 88/402,115.5).

The fact that conventional submerged fermentation techniques can be used to produce Bt spores on a large scale makes Bt bacteria commercially attractive as a source of insecticidal compositions.

Gene fragments from some Bt strains, encoding insecticidal proteins, have heretofore been identified and integrated into plant genomes in order to render the plants insect-resistant. However, obtaining expression of such Bt gene fragments in plants is not a straightforward problem. To achieve optimal expression of an insecticidal protein in plant cells, it has been found necessary to engineer each Bt gene fragment in a specific way so that it encodes a water-soluble part of a Bt protoxin that retains substantial toxicity against its target insects (European patent applications 86/300,291.1 and 88/402,115.5; U.S. patent application 821,582, filed January 22, 1986)

### Summary of the Invention

In accordance with this invention, the two new Bt strains of pathotype C, i.e., the BtPGSI208 and BtPGSI245 strains, are provided. The BtPGSI208 and BtPGSI245 crystals, crystal proteins, protoxins and toxins, produced by the respective strains during sporulation, as well as insecticidally effective portions of the BtPGSI208 and BtPGSI245 protoxins, each possess insecticidal activity and can therefore be formulated into insecticidal compositions against Coleoptera in generally especially against *Leptinotarsa decemlineata*, *Agelastica alni*, *Diabrotica luteola*, *Haltica tombacina*, *Anthonomus grandis*, *Tenebrio molitor* and *Triboleum castaneum* and particularly against the Colorado potato beetle, *Leptinotarsa decemlineata*, which is a major pest of economically important crops.

Also in accordance with this invention, a plant cell genome is transformed with the insecticidally effective btPGSI208 or btPGSI245 gene part, preferably the truncated btPGSI208 or btPGSI245 gene. It is preferred that this transformation be carried with the btPGSI208 or btPGSI245 chimaeric gene. The resulting transformed plant cell can be used to produce a transformed plant in which the plant cells in some or all of the plant tissues: 1) contain the insecticidally effective btPGSI208 or btPGSI245 gene part as a stable insert in their genome and 2) express the insecticidally effective btPGSI208 or btPGSI245 gene part by producing an insecticidally effective portion of its respective BtPGSI208 or BtPGSI245 protoxin, preferably its respective BtPGSI208 or BtPGSI245 toxin, thereby rendering the plant resistant to Coleoptera.

Yet further in accordance with this invention, a process is provided for rendering a plant resistant to Coleoptera by transforming the plant cell genome with the insecticidally effective btPGSI208 or btPGSI245 gene part, preferably the truncated btPGSI208 or btPGSI245 gene. In this regard, it is preferred that the plant cell be transformed with the btPGSI208 or btPGSI245 chimaeric gene.

Still further in accordance with this invention, there are provided the BtPGSI208 and BtPGSI245 protoxins, the insecticidally effective portions of such protoxins and the BtPGSI208 and BtPGSI245 toxins, as well as the btPGSI208 and btPGSI245 genes, the insecticidally effective btPGSI208 and btPGSI245 gene parts, the truncated btPGSI208 and btPGSI245 genes and the chimaeric btPGSI208 and btPGSI245 genes.

### Detailed Description of the Invention

In accordance with this invention, the BtPGSI208 and BtPGSI245 protoxins can be isolated in a conventional manner from, respectively, the BtPGSI208 strain, deposited at the DSM under accession number 5131, and the BtPGSI245 strain, deposited at the DSM under accession number 5132. For example, the BtPGSI208 and BtPGSI245 crystals can be isolated from sporulated cultures of their respective strains (Mahillon and Delcour, 1984), and then, the respective protoxins can be isolated from these crystals according to the method of Höfte et al (1986). The protoxins can be used to prepare monoclonal or polyclonal antibodies specific for these protoxins in a conventional manner (Höfte et al, 1988). The BtPGSI208 toxin can then be obtained by removing (e.g., by trypsin digestion) approximately 57 N-terminal amino acids from the BtPGSI208 protoxin. The BtPGSI245 toxin can be obtained by removing (e.g., by trypsin digestion) approximately 52 N-terminal and approximately 501 C-terminal amino acids from the BtPGSI245 protoxin.

The btPGSI208 and btPGSI245 genes can also be isolated from their respective strains in a conventional manner. For example, the btPGSI208 or btPGSI245 gene can be identified in its respective BtPGSI208 or BtPGSI245 strain, using the procedure described in U.S. patent application 821,582 and in European patent applications 86/300,291.1 and 88/402,115.5 (which are incorporated herein by reference). Preferably, the btPGSI208 and btPGSI245 genes are each identified by: digesting total DNA from their

respective BtPGSI208 and BtPGSI245 strains with one or more restriction enzymes; size fractionating the DNA fragments, so produced, into DNA fractions of 5 to 10 Kb; ligating such fractions to cloning vectors; transforming *E. coli* with the cloning vectors; and screening the clones with a suitable DNA probe. The DNA probe can be constructed: 1) from a highly conserved region of a Bt gene which codes for another crystal protoxin against Coleoptera such as: the bt13 gene described in European patent application 88/402,115.5 and by Höfte et al (1987); or 2) on the basis of the N-terminal amino acid sequence of the protoxin encoded by the respective btPGSI208 or btPGSI245 gene, which sequence can be determined by gas-phase sequencing of the immobilized protoxin (European Patent application 88/402,115.5).

Alternatively, the 5 to 10 kb fragments, prepared from total DNA of the BtPGSI208 or BtPGSI245 strain, can be ligated in suitable expression vectors and transformed in *E. coli*, and the clones can then be screened by conventional colony immunoprobng methods (French et al, 1986) for expression of the BtPGSI208 or BtPGSI245 toxin with monoclonal or polyclonal antibodies raised against the toxin.

The so-identified btPGSI208 and btPGSI245 genes can then each be sequenced in a conventional manner (Maxam and Gilbert, 1980) to obtain the DNA sequences shown in Figs. 1 and 2, respectively.

A truncated part of each of the sequenced genes, encoding an insecticidally effective portion of its protoxin and preferably encoding just its toxin, can be made in a conventional manner from the gene after the gene has been sequenced. The amino acid sequences of the BtPGSI208 and BtPGSI245 protoxins and toxins can be determined from the DNA sequences of their respective btPGSI208 and btPGSI245 genes and truncated btPGSI208 and btPGSI245 genes

The insecticidally effective btPGSI208 or btPGSI245 gene part, encoding an insecticidally effective portion of its respective BtPGSI208 or BtPGSI245 protoxin, can be stably inserted in a conventional manner into the nuclear genome of a single plant cell, and the so-transformed plant cell be used in a conventional manner to produce a transformed plant that is insect-resistant. In this regard, a disarmed Ti-plasmid, containing the insecticidally effective btPGSI208 or btPGSI245 gene part, in *Agrobacterium tumefaciens* can be used to transform the plant cell, and thereafter, a transformed plant can be regenerated from the transformed plant cell using the procedures described, for example, in European patent publication 0,116,718, PCT publication WO 84/02,913 and European patent application 87/400,544.0 (which are also incorporated herein by reference). The resulting transformed plant can be used in a conventional plant breeding scheme to produce more transformed plants with the same characteristics or to introduce the insecticidally effective btPGSI208 or btPGSI245 gene part in other varieties of the same or related plant species. Seeds, which are obtained from the transformed plants, contain the insecticidally effective btPGSI208 or btPGSI245 gene part as a stable genomic insert.

The insecticidally effective btPGSI208 or btPGSI245 gene part, preferably the truncated btPGSI208 or btPGSI245 gene, is inserted in a plant cell genome so that the inserted part of the gene is downstream of, and under the control of, a promoter which can direct the expression of the gene part in the plant cell. This is preferably accomplished by inserting the btPGSI208 or btPGSI245 chimaeric gene in the plant cell genome. Preferred promoters include: the strong constitutive 35S promoters (the "35S promoters") of the cauliflower mosaic virus of isolates CM 1841, Gardner et al, 1981), CabbB-S (Franck et al, 1980) and CabbB-J1 (Hull and Howell, 1987); and the TR1' promoter and the TR2' promoter (the "TR1' promoter" and "TR2' promoter", respectively) which drive the expression of the 1' and 2' genes, respectively, of the T-DNA (Velten et al, 1984). Alternatively, a promoter can be utilized which is not constitutive but rather is specific for one or more tissues or organs of the plant (e.g., leaves and/or roots) whereby the inserted btPGSI208 or btPGSI245 gene part is expressed only in cells of the specific tissue(s) or organ(s). For example, the btPGSI208 or btPGSI245 gene part could be selectively expressed in the leaves of a plant (e.g., potato) by placing the gene part under the control of a light-inducible promoter such as the promoter of the ribulose-1,5-bisphosphate carboxylase small subunit gene of the plant itself or of another plant such as pea as disclosed in U.S. patent application 821,582 and European patent application 86/300,291.1. Another alternative is to use a promoter whose expression is inducible (e.g., by temperature or chemical factors).

The insecticidally effective btPGSI208 or btPGSI245 gene part is inserted in the plant genome so that the inserted part of the gene is upstream of suitable polyadenylation and transcription termination signals. This is preferably accomplished by inserting the btPGSI208 or btPGSI245 chimaeric gene in the plant cell genome. Preferred polyadenylation and transcription termination signals include those of the octopine synthase gene (Gielen et al, 1984) and the T-DNA gene 7 (Velten and Schell, 1985), which act as 3'-untranslated DNA sequences in transformed plant cells.

It is preferred that the inserted insecticidally effective btPGSI208 or btPGSI245 gene part be in the same transcriptional unit as, and under the control of, the same promoter as a selectable marker gene. This is preferably accomplished by inserting a btPGSI208 or btPGSI245 chimaeric gene, containing the marker

gene, in the plant cell genome. Any conventional marker gene can be utilized, the expression of which can be used to select transformed plant cells. An example of a suitable selectable marker gene is an antibiotic resistance gene such as the *neo* gene coding for kanamycin resistance (Reiss et al, 1984; European patent application 87/400,544.0; U.S. patent application 821,582; European patent application 86/300,291.1).

5 Thereby, the insecticidally effective *btPGSI208* or *btPGSI245* gene part and the marker gene (e.g., the *btPGSI208-neo* or *btPGSI245-neo* hybrid gene) are expressed in a transformed plant as a fusion protein (U.S. patent application 821,582; European patent application 86/300,291.1; Vaeck et al, 1987).

Each of the *BtPGSI208* and *BtPGSI245* strains can be fermented by conventional methods (Dulmage, 1981) to provide high yields of cells. Under appropriate conditions which are well understood (Dulmage, 1981), the *BtPGSI208* and *BtPGSI245* strains each sporulate to provide their respective *BtPGSI208* and *BtPGSI245* crystal proteins in high yields.

An insecticide composition of this invention can be formulated in a conventional manner using the *BtPGSI208* or *BtPGSI245* strain or preferably their respective crystals, crystal proteins, protoxin, toxin and/or insecticidally effective portions of their respective protoxin, as active ingredient(s), together with suitable carriers, diluents, emulsifiers and/or dispersants. This insecticide composition can be formulated as a wettable powder, pellets, granules or a dust or as a liquid formulation with aqueous or non-aqueous solvents as a foam, gel, suspension, concentrate, etc. The concentration of the *BtPGSI208* or *BtPGSI245* strain, crystals, crystal proteins, protoxin, toxin and/or protoxin portions in such a composition will depend upon the nature of the formulation and its intended mode of use. Generally, an insecticide composition of this invention can be used to protect a potato field for 2 to 4 weeks against Coleoptera with each application of the composition. For more extended protection (e.g., for a whole growing season), additional amounts of the composition should be applied periodically.

The following examples illustrate the invention. The figures, referred to in the examples, are as follows :

Figure 1 - DNA sequence of the *btPGSI208* gene. The derived aminoacid sequence of the encoded *BtPGSI208* protoxin is presented beneath this sequence. The arrow separates the N-terminal 57 aminoacids from the C-terminal portions encoding the *BtPGSI208* toxin.

Figure 2 - DNA sequence of the *btPGSI245* gene. The derived aminoacid sequence of the encoded *BtPGSI245* protoxin is presented beneath this sequence. The arrows delineate the *BtPGSI245* toxin between aminoacids 54 and 638 of the *BtPGSI245* protoxin.

Figure 3 - Total protein patterns by SDS-PAGE of sporulated *BtPGSI208* and *BtPGSI245* and other *Bacillus* cultures. Among the comparison strains, *B. subt.* is *Bacillus subtilis*, *B. cer.* is *Bacillus cereus*, and *Bt Darm* is *Bacillus thuringiensis* subsp. *darmstadensis*. These comparison strains were obtained from the sources set forth in Table 1, hereinafter. "MW" designates molecular weight markers.

Figure 4A- Protein blotting of total proteins and trypsinized crystal proteins from strains *BtS1* and *BtPGSI208*. Total protein patterns were stained with Indian ink, while crystal proteins were visualized with an antiserum against *Bt13* toxin ("anti-CryIIIA"). "HMW" designates molecular weight markers.

Figure 4B- Protein blotting of total proteins and trypsinized crystal proteins from strains *BtS1*, *BtPGSI245* and *Bt HD-110*. Total protein patterns were probed for their immunoreactivity with an antiserum against *Bt13* toxin ("anti-CryIIIA") and an antiserum against *Bt2* protoxin ("anti-CryIA(b)"). "LMW" designates molecular weight markers. The comparison strain, *HD-110*, was *Bt HD-110*, obtained from Dr. H. Dulmage, Cotton Insect Laboratories, U.S.D.A., Brownsville, Texas, U.S.A.

Unless otherwise stated in the Examples, all procedures for making and manipulating recombinant DNA are carried out by the standardized procedures described in Maniatis et al, Molecular Cloning - A laboratory Manual, Cold Spring Harbor Laboratory (1982).

#### Example 1 : Characterization of the *BtPGSI208* and *BtPGSI245* strains

The *BtPGSI208* strain was isolated from grain dust sampled in Belgium and was deposited at the DSM on January 19, 1989 under accession No. 5131.

The *BtPGSI245* strain was isolated from cow dung sampled in the United States and was deposited at the DSM on January 19, 1989 under accession No. 5132.

Each strain can be cultivated on conventional standard media, preferably LB medium (Bacto-tryptone 10 g/l, yeast extract 5 g/l, NaCl 10 g/l and agar 15 g/l), preferably at 28°C. For long term storage, it is preferred to use LB liquid medium containing 50% glycerol at -70°C or lyophilization. For sporulation, the use of T<sub>3</sub> medium (tryptone 3 g/l, tryptose 2 g/l, yeast extract 1.5 g/l, 5 mg MnCl<sub>2</sub>, 0.05 M Na<sub>2</sub>PO<sub>4</sub>, pH 6.8 and 1.5% agar) is preferred for 24 hours at 28°C, followed by storage at 4°C. During its vegetative phase, each of the *BtPGSI208* and *BtPGSI245* strains can also grow under facultative anaerobic conditions, but

sporulation only occurs under aerobic conditions.

Sterilization of each strain occurs by autoclave treatment at 120 °C (1 bar pressure) for 20 minutes. Such treatment totally inactivates the spores and the crystalline BtPGSI208 and BtPGSI245 protoxins. UV radiation (254 nm) inactivates the spores but not the protoxins.

- 5 After cultivating on Nutrient Agar ("NA", Difco Laboratories, Detroit, MI, USA) for one day, colonies of each of the BtPGSI208 and BtPGSI245 strains form opaque white colonies with irregular edges. Cells of each strain (Gram positive rods of 1.7-2.4 x 5.6-7.7 µm) sporulate after three days cultivation at 28 °C on NA.

- 10 The crystal proteins produced during sporulation are packaged in flat rhomboid crystals in the BtPGSI208 strain and in bipyramidal crystals in the BtPGSI245 strain. Both of these crystal forms are clearly different from the flat square crystals of the BtS1 strain (from DSM under accession no. 4288) or Bt tenebrionis (from DSM under accession no. 2803).

- For the biochemical characterization of the two strains, the following tests were carried out using well known methods as described for example by Sneath et al (1986). Growth was observed in Nutrient Broth ("NB", Difco) supplemented with 2 and 5% NaCl. No growth of the BtPGSI208 strain and only weak growth of the BtPGSI245 strain were observed in the presence of 7% NaCl. Neither strain grew in medium supplemented with 10% NaCl. The BtPGSI208 and BtPGSI245 strains grew well on NA at 20, 28 and 37 °C, but not at 4, 10 (although the BtPGSI245 strain grew slowly at this temperature), 50 and 60 °C. Both strains grew in NB at pH = 5, pH = 6 and pH = 7 and on NB containing 100 units of lysozyme (Sigma Chemical Company, St Louis, MO, USA) per ml of NB. Growth on NA under anaerobiosis was very weak.

Metabolic characteristics of the two strains were determined using API-20E test strips (API Systems S.A., Montalieu-Vercieu, France). The results of these assays are shown in Table 1, below.

Table 1

Metabolic characteristics of the BtPGSI208 and BtPGSI245 strains as compared with other Bacillus strains							
(+ = positive reaction ; - = negative reaction ; w = weak reaction ; nd = not determined).							
Activity	Bt PGSI 208	Bt PGSI 245	BTS1	BTEN	BDAR	BCER	BSUB
ONPG	-	-	-	-	-	-	+
ADH	-	+	+	+	+	+	-
LDC	-	-	-	-	-	-	-
ODC	-	-	-	-	-	-	-
CIT	-	-	-	-	-	-	-
H <sub>2</sub> S	-	-	-	-	-	-	-
URE	-	-	-	-	-	-	-
TDA	-	-	-	+	w	+	+
IND	-	-	-	-	-	-	-
VP	-	-	-	w	w	w	+
GEL	-	+	-	+	+	+	+
OX	+	+	+	+	+	+	+
NO <sub>2</sub>	+	+	+	+	+	+	nd
N <sub>2</sub>	-	-	-	-	-	-	nd

- 50 ONPG =  $\beta$ -galactosidase activity.  
 DH = arginine dihydrolase activity.  
 LDC = lysine decarboxylase activity.  
 ODC = ornithine decarboxylase activity.  
 CIT = use of citrate as sole carbon source.  
 55 H<sub>2</sub>S = H<sub>2</sub>S formation from thiosulphate.  
 URE = urease activity.  
 TDA = tryptophan deaminase activity.  
 IND = indol formation from tryptophan.

VP = acetoin formation from sodium pyruvate.

GEL = gelatin liquefaction.

OX = oxidase activity.

NO<sub>2</sub> = nitrate reduction to nitrite.

5 N<sub>2</sub> = N<sub>2</sub> gas production from nitrate.

BTS1 = Bacillus thuringiensis BtS1 from DSM under accession no. 4288.

BTEN = Bacillus thuringiensis subsp. tenebrionis from DSM under accession no. 2803.

10 BDAR = Bacillus thuringiensis subsp. darmstadiensis from (Institut für Landwirtschaftliche Bacteriologie und Gärungsbiologie der Eidgenössische Technische Hochschule, Zürich, Switzerland ("LBG"), under accession no. 4447

BCER = Bacillus cereus from Laboratorium voor Microbiologie, Gent, Belgium ("LMG"), under accession no. 2098.

BSUB = Bacillus subtilis from Agricultural Research Culture Collection, Peoria, Illinois, USA, under accession no. NRRL B-237.

15 Both strains were found to rapidly decompose casein in skim-milk agar and to deaminate phenylalanine in tests described by Sneath et al (1986).

Acid production from different sugars by the two strains was determined using API-50CHB test strips (API Systems SA). The results are shown in Table 2, below.

20

25

30

35

40

45

50

55

**Table 2:** Acid production by the BtPGSI208 and BtPGSI245 strains as compared with other bacilli (+ = positive reaction ; - = negative reaction ; w = weak reaction).

Substrate :	Bt PGSI 208	Bt PGSI 245	BtS1	BTEN	BDAR	BCER	BSUB
Control	-	-	-	-	-	-	-
Glycerol	-	w	+	+	+	+	+
Erythritol	-	-	-	-	-	-	-
D-arabinose	-	-	-	-	-	-	-
L-arabinose	-	-	-	-	-	-	+
Ribose	+	+	+	+	+	+	+
D-Xylose	-	-	-	-	-	-	+
L-Xylose	-	-	-	-	-	-	-
Adonitol	-	-	-	-	-	-	-
B Methyl-xyloside	-	-	-	-	-	-	-
Galactose	-	-	-	-	-	-	+
D-Glucose	+	+	+	+	+	+	+
D-Fructose	+	+	+	+	+	+	+
D-Mannose	-	+	+	+	-	-	+
L-Sorbose	-	-	-	-	-	-	-
Rhamnose	-	-	-	-	-	-	-
Dulcitol	-	-	-	-	-	-	-
Inositol	-	-	-	-	-	-	+
Mannitol	-	-	-	-	-	-	+
Sorbitol	-	-	-	-	-	-	+
$\alpha$ -Methyl-D-mannoside	-	-	-	-	-	-	-
$\alpha$ -Methyl-D-glucoside	-	-	-	-	-	-	+
N-Acetylglucosamide	+	+	+	+	+	+	-
Amygdaline	-	-	-	-	-	-	+
Arbutine	+	+	+	+	+	-	+
Esculine	+	+	+	+	+	+	+
Salicine	+	w	-	-	-	-	+
Cellobiose	-	w	-	-	-	-	+
Maltose	+	+	+	+	+	+	+
Lactose	-	-	-	-	-	-	+
Melibiose	-	-	-	-	-	-	+
Saccharose	+	+	+	+	-	+	+
Trehalose	+	+	+	+	+	+	+
Inuline	-	-	-	-	-	-	+

Table 2 (C ntinued)

Substrate :	Bt PGSI 208	Bt PGSI 245	BtS1	BTEN	BDAR	BCER	BSUB
Melizitose	-	-	-	-	-	-	-
D-Raffinose	-	-	-	-	-	-	+
Starch	+	+	+	+	+	+	+
Glycogen	+	+	+	+	+	+	+
Xylitol	-	-	-	-	-	-	-
B Gentiobiose	-	-	-	-	-	-	-
D-Turanose	-	-	-	-	-	-	+
D-Lyxose	-	-	-	-	-	-	-
D-Tagatose	-	-	-	-	-	-	-
D-Fucose	-	-	-	-	-	-	-
L-Fucose	-	-	-	-	-	-	-
D-Arabitol	-	-	-	-	-	-	-
L-Arabitol	-	-	-	-	-	-	-
Glucanate	-	-	-	-	-	-	-
2 Ketogluconate	-	-	-	-	-	-	-
5 Ketogluconate	-	-	-	-	-	-	-

Sensitivity of the two strains towards different antibiotics was tested using Oxoid Susceptibility Test Discs on Oxoid Isosensitest agar ("CM471" of Oxoid Ltd., Basingstoke, Hampshire, England). The results are shown in Table 3, below.

Table 3

Antibiotic sensitivity as shown by the diameters (in mm) of inhibition zones observed after 24 hours on antibiotic-containing agar, seeded with different bacilli								
(R = resistant colonies or no growth detected).								
Antibiotic	amount/disc	Bt PGSI 208	Bt PGSI 245	BtS1	BTEN	BDAR	BCER	BSUB
Chloramphenicol	30 ug	25/R	17	19/R	20	22	28	33
Bacitracin	10 i.u	11	10	8	7	14	18	7
Gentamycin	10 ug	26	20	21	20	28	9	25/R
Neomycin	30 ug	24	20/R	13/R	13	26	10	20
Tetracyclin	30 ug	14/R	10	17/R	16/R	10/R	21	22
Carbenicillin	100 ug	8	11	0	0	10	0	19
Rifampicin	2 ug	12	13	0	8	8	19	26
Penicillin G	10 i.u	7	8	0	0	0	14/R	14
Streptomycin	10 ug	25/R	15	16	17	20	14	0
Spectinomycin	10 ug	0	0	0	0	0	12/R	0
Kanamycin	30 ug	20/R	21/R	0	0	24	15	24
Nalidixic acid	30 ug	25/R	23/R	18/R	25/R	30/R	7	19
Sulphamethoxazole	25 ug	0	0	0	0	0	0	0
Trimethoprim	2.5 ug	0	0	0	0	0	0	26
Ampicillin	10 u	7	9/R	0	0	0	15/R	18

The enzyme spectra of the BtPGSI208 and BtPGSI245 strains were determined using the extended API-ZYM strips (API Systems S.A.). The results are shown in Table 4, below. Esterase-, peptidase- (AP1, AP2, AP3, AP4, AP5 and AP6 test strips) and osidase-test strips were inoculated with 50 µl cell suspension

( $10^7$  cfu/ml). The osidase reaction was revealed after 4 hours incubation ( $28^\circ\text{C}$ ) with 25  $\mu\text{l}$  0.1N NaOH. All other reactions were with 25  $\mu\text{l}$  ZYM A and ZYM B reagent (API no. 7048).

Table 4

Enzymatic spectra of the BtPGSI208 and BtPGSI245 strains as compared to two other Bt strains				
(0 = no substrate used; 1, 2, 3, 4, 5 = 5, 10, 20, 30 and $\geq 40$ nanomoles of substrate hydrolysed respectively).				
Substrate	Bt PGSI 208	Bt PGSI 245	BTS1	BDAR
<b>Esterases.</b>				
2-naphtyl-valerate	4	4	2	4
2-naphtyl-caproate	5	5	5	5
2-naphtyl-caprylate	5	5	5	5
2-naphtyl-nonanoate	5	5	4	5
2-naphtyl-caprate	5	3	3	5
2-naphtyl-laurate	2	2	1	2
2-naphtyl-myristate	1	2	1	1
2-naphtyl-palmitate	0	0	1	0
2-naphtyl-stearate	2	1	2	2
<b>Peptidases.</b>				
L-pyrrolidonyl- $\beta$ -naphtylamide	0	5	5	5
Glycyl- $\beta$ -naphtylamide	0	0	0	0
L-glutamyl- $\beta$ -naphtylamide	0	0	0	0
L-leucyl-glycyl- $\beta$ -naphtylamide	0	1	0	0
L-seryl-L-tyrosyl- $\beta$ -naphtylamide	4	5	5	5
L-glutamine- $\beta$ -naphtylamide	1	5	4	5
L-glutamyl- $\beta$ -naphtylamide	0	3	3	3
<b>Osidasases.</b>				
Paranitrophenol-D-galactopyranoside	0	0	0	0
Paranitrophenol- $\beta$ D-galactopyranoside	0	0	0	0
Paranitrophenol-aD-glucopyranoside	5	5	5	5
Paranitrophenol- $\beta$ D-glucopyranoside	0	2	0	0
Paranitrophenol-a-maltoside	2	4	3	5
Paranitrophenol- $\beta$ -maltoside	0	0	0	0
Paranitrophenol-N-acetyl- $\beta$ D-glucosamidine	3	5	5	5
Paranitrophenol- $\beta$ D-xylapyranoside	0	0	0	0

#### Example 2: Characteristics of the BtPGSI208 and BtPGSI245 crystals

The BtPGSI208 and BtPGSI245 strains were grown for 48 to 72 hours at  $28^\circ\text{C}$  on  $T_3$  medium. After sporulation, the spores and crystals were harvested in phosphate buffered saline solution ("PBS" from Oxoid Ltd.) by scraping with a Trihalski spatula. The resulting aqueous spore-crystal suspensions were centrifuged, and the pellets were resuspended and incubated overnight in aqueous solutions containing 50mM  $\text{Na}_2\text{CO}_3$  and 5mM dithiotreitol ("DTT") at pH 10. After centrifugation, the supernatants were recovered containing the respective crystal proteins.

The BtPGSI208 protoxin and toxin, as well as the BtPGSI245 toxin, react only with a polyclonal antiserum raised against the Bt13 toxin as shown in Fig. 4. In contrast, the BtPGSI245 protoxin reacts with polyclonal antisera against the Bt13 toxin and the Bt2 protoxin (U.S. patent application 821,582; European

patent application 86/300,291.1) as shown in Fig. 4.

The total protein patterns of the BtPGSI208 and BtPGSI245 strains, compared to other *Bacillus* strains, are shown in Fig. 3. For this comparison, the crystal proteins of each strain were analyzed on a 12.5% SDS-PAGE gel (Laemmli, 1970) and stained with Coomassie brilliant blue R-250 according to Lambert et al (1987). The crystal proteins were dissolved by exposing the spore-crystal mixtures overnight at 37 °C to 50 mM Na<sub>2</sub>CO<sub>3</sub>, pH 10, 5 mM DTT. Solubilized crystal proteins were digested by adjusting the pH to 9.0 with 0.5 M HCl and by trypsinization (1 µg bovine trypsin/25 µg protein). Trypsin digestion of the BtPGSI208 and BtPGSI245 crystal proteins was performed at 37 °C overnight and revealed the presence of tryptic fragments of 68 kDa (Fig. 4). Immunoblotting experiments, performed according to Peferoen (1988) with polyclonal antisera raised against the Bt13 toxin and the Bt2 protoxin demonstrated, in Figs. 4A and B, that the BtPGSI208 and BtPGSI245 protoxins and toxins are immunologically related to the Bt13 toxin. In addition, the BtPGSI245 protoxin was also shown, in Fig. 4B, to be immunologically related to the Bt2 protoxin. After blotting, the proteins were stained with Indian ink (Sutherland and Skerritt, 1986) to show both immunoreactive and non-immunoreactive proteins (Fig. 4).

### Example 3: Insecticidal activity of the BtPGSI208 and BtPGSI245 crystal proteins

As in Example 2, both strains were grown for 48 to 72 hrs at 28 °C on T<sub>3</sub> medium. After sporulation, the spores and crystals were harvested in PBS with a Trihalski spatula. The resulting spore-crystal suspensions were centrifuged, and the pellets were resuspended and incubated overnight in aqueous Na<sub>2</sub>CO<sub>3</sub> and DTT solutions as described in Example 2. After centrifugation, the supernatants were recovered, and their contents of the respective crystal proteins of the two strains were determined.

Potato leaves were dipped in aqueous dilutions of the supernatant solutions and then air dried for two hours. Colorado potato beetle larvae of the second instar were placed on the treated leaves, and mortality of the larvae was measured after three days. These results were compared with the mortality of larvae fed leaves treated with solubilized crystals of Bt HD-1 ("Bt kurstaki Dipel" from Abbott Laboratories, Abbott Park, North Chicago, Ill., USA) as a control. LC<sub>50</sub>, expressed as µg of solubilized crystals/ml, was calculated by Probit analysis (Finney, 1971). The results are summarized in Table 5, below.

Table 5

Strain	LC50	FL95min	FL95max	Slope
BtPGSI208	5.0	3.5	7.3	2.4
BtPGSI245	25.1	14.7	43.3	1.5
Control	>500	-	-	-

### Example 4: Identification and cloning of the btPGSI208 gene

The BtPGSI208 protoxin from the BtPGSI208 strain was detected by ELISA (Engvall and Pesce, 1978) with a polyclonal antiserum against the Bt13 coleoptera toxin (Höfte et al, 1987). The btPGSI208 gene was identified in the BtPGSI208 strain by preparing total DNA of the BtPGSI208 strain and then digesting the DNA with the restriction enzymes HindIII, EcoRI and ClaI. The so-digested DNA was analyzed by Southern blotting, probing with a nick-translated 2.9 kb HindIII fragment from the genome of the BtS1 strain (European patent application 88/402,115.5) containing the bt13 gene. After hybridization with the probe, the blot was washed under low stringency conditions (2XSSC, 0.1% SDS at 68 °C for 2x15 min), showing the presence of the btPGSI208 gene, related to the bt13 gene. The hybridization pattern with the probe also showed that the btPGSI208 gene was clearly different from the bt13 gene.

In order to isolate the btPGSI208 gene, total DNA was prepared from the BtPGSI208 strain. The total DNA preparation was partially digested with Sau3A and was size-fractionated on a sucrose gradient. Fractions containing DNA between 5 kb and 10 kb were ligated to the BglII-digested and bovine alkaline phosphatase ("BAP")-treated cloning vector pEcor251 (Deposited at the DSM on July 13, 1988 under accession number DSM 4711). Recombinant *E. coli* clones containing the vector were then screened with

the 2.9 kb HindIII DNA fragment containing the bt13 gene, as a probe, to identify DNA fragments of clones containing the btPGSI208 gene. The so-identified DNA fragments were then sequenced according to Maxam and Gilbert (1980).

Based on the analysis of the DNA sequence of the btPGSI208 gene, the gene is cut with an appropriate restriction enzyme to give the truncated btPGSI208 gene, encoding the BtPGSI208 toxin of about 67 kDa.

#### Example 5: Identification and cloning of the btPGSI245 gene

The BtPGSI245 protoxin from the BtPGSI245 strain was detected by ELISA (Engvall and Pesce, 1978) with a polyclonal antiserum directed against the Bt13 coleoptera toxin. Colony hybridization of the BtPGSI245 strain and Southern blotting of the BtPGSI245 total DNA, that had been probed with the 2.9 kb HindIII DNA fragment containing the bt13 gene and washed under the previously described low stringency conditions, revealed no hybridizing DNA.

In order to isolate the btPGSI245 gene, total DNA from the BtPGSI245 strain was prepared and partially digested with Sau3A. The digested DNA was size fractionated on a sucrose gradient and fragments ranging from 5 kb to 10 kb were ligated to the BamHI-digested and BAP-treated cloning vector pUC18 (Yannisch-Perron et al, 1985). Recombinant clones containing the vector were then screened by colony immunoprobng (French et al, 1986) with an antiserum against the Bt13 toxin. Positive colonies were purified, and total protein preparations were again analyzed by immunoblotting with the antiserum against the Bt13 toxin. DNA fragments, containing the BtPGSI245 gene, from clones expressing the BtPGSI245 protoxin, were then sequenced according to Maxam and Gilbert (1980).

Based on the analysis of the DNA sequence of the btPGSI245 gene, the gene is cut with an appropriate restriction enzyme to give the truncated btPGSI245 gene, encoding the BtPGSI245 toxin of about 66 kDa.

#### Example 6: Construction of a btPGSI208-neo hybrid gene and a btPGSI245-neo hybrid gene

Following the procedure of European patent application 88/402,115.5, the truncated btPGSI208 and btPGSI245 genes from Examples 4 and 5, respectively, are each fused to the neo gene to form the corresponding hybrid gene.

#### Example 7: Insertion of the btPGSI208 and btPGSI245 genes, the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes in E. coli and insertion of the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes in potato plants

The btPGSI208 and btPGSI245 genes and the truncated btPGSI208 and btPGSI245 genes from Examples 4 and 5 and the btPGSI208-neo and btPGSI245-neo hybrid genes from Example 6 are each inserted into, and expressed by, different E. coli in a conventional manner, using E. coli expression vectors as described by Botterman and Zabeau (1987).

Using the procedures described in U.S. patent application 821,582 and European patent application 86/300,291.1 and 88/402,115.5, the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes are inserted into intermediate plant expression vectors. To provide major expression in plants, the hybrid genes and truncated genes are placed under the control of strong constitutive promoters such as the Cabb-J1 35S promotor (Hull and Howell, 1987) or the TR2' promotor (Velten et al, 1984) and are fused to transcription termination and polyadenylation signals such as those of the octopine synthase gene (Gielen et al, 1984).

Using standard procedures (Deblaere et al, 1985), the intermediate plant expression vectors, containing the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes are transferred into the Agrobacterium strain C 58 C1 Rif<sup>R</sup> (US patent application 821,582; European patent application 86/300,291.1) carrying the disarmed Ti-plasmid pGV2260 (Vaeck et al, 1987). Selection for spectinomycin resistance yields cointegrated plasmids, consisting of pGV2260 and the respective intermediate plant expression vectors. Each of these recombinant Agrobacterium strains is then used to transform different potato plant cells so that the truncated btPGSI208 gene, the truncated btPGSI245 gene, the btPGSI208-neo hybrid gene and the btPGSI245-neo hybrid gene are contained in, and expressed by, different cells.

Example 8: Expression of the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes in potato plants

The insecticidal activity against Coleoptera of the expression products of the truncated btPGSI208 and btPGSI245 genes and the btPGSI208-neo and btPGSI245-neo hybrid genes in leaves of transformed potato plants, generated from the transformed potato plant cells of Example 7, is evaluated by recording the growth rate and mortality of Leptinotarsa decemlineata larvae fed on these leaves. These results are compared with the growth rate of larvae fed leaves from untransformed potato plants. Toxicity assays are performed as described in European Patent application 88/402,115.5, U.S. patent application 821,582 and European patent application 86/300,291.1. A significantly higher mortality rate is obtained among larvae fed on leaves of transformed potato plants containing the truncated btPGSI208 gene, the truncated btPGSI245 gene, the btPGSI208-neo hybrid gene or the btPGSI245-neo hybrid gene than among larvae fed the leaves of untransformed plants.

Needless to say, this invention is not limited to the BtPGSI208 (DSM 5131) strain and the BtPGSI245 (DSM 5132) strain. Rather, the invention also includes any mutant or variant of the BtPGSI208 or BtPGSI245 strain which produces crystals, crystal proteins, protoxin or toxin having substantially the same properties as the BtPGSI208 or BtPGSI245 crystals, crystal proteins, protoxin or toxin. In this regard, variants of the BtPGSI208 and BtPGSI245 strains include variants whose total protein pattern is substantially the same as the protein pattern of either the BtPGSI208 strain or the BtPGSI245 strain as shown in Fig. 3.

This invention also is not limited to potato plants transformed with the truncated btPGSI208 or btPGSI245 gene. It also includes any plant, such as tomato, tobacco, rapeseed, alfalfa, sunflowers, cotton, corn, soybeans, potato, brassicas, sugar beets and other vegetables, transformed with an insecticidally effective part of the btPGSI208 or btPGSI245 gene.

Nor is this invention limited to the use of Agrobacterium tumefaciens Ti-plasmids for transforming plant cells with an insecticidally effective btPGSI208 or btPGSI245 gene part. Other known techniques for plant cell transformations, such as by means of liposomes, by electroporation or by vector systems based on plant viruses or pollen, can be used for transforming monocotyledons and dicotyledons with such a gene part.

Furthermore, DNA sequences other than those of an insecticidally effective btPGSI208 or btPGSI245 gene part can be used for transforming plants. In this regard, the DNA sequence of either gene part can be modified by: 1) replacing some codons with others that code either for the same amino acids or for other amino acids; and/or 2) deleting or adding some codons; provided that such modifications do not substantially alter the properties of the encoded, insecticidally effective portion of the BtPGSI208 or BtPGSI245 protoxin.

Also, other DNA recombinants containing the aforementioned DNA sequences in association with other foreign DNA, particularly the DNA of vectors suitable for transforming plants and microorganisms other than E. coli, are encompassed by this invention. In this regard, this invention is not limited to the specific plasmids containing the btPGSI208 and btPGSI245 genes, or parts thereof, that were heretofore described, but rather, this invention encompasses any DNA recombinants containing a DNA sequence that is their equivalent. Further, the invention relates to all DNA recombinants that include all or part of either the btPGSI208 gene or the btPGSI245 gene and that are suitable for transforming microorganisms (e.g., plant associated bacteria such as Bacillus subtilis, Pseudomonas, and Xanthomonas or yeasts such as Streptomyces cerevisiae) under conditions which enable all or part of the gene to be expressed and to be recoverable from said microorganisms or to be transferred to a plant cell.

#### References

- Botterman and Zabeau, DNA 6, 583-591 (1987)
- Deblaere, R., Billebier, B. De Greve, H., Debock, F., Schell, J., Van Montagu, M. and Leemans, J., Nucleic Acids Research 13, 4777-4788 (1985).
- Dulmage, H.T., "Production of Bacteria for Biological Control of Insects" in Biological Control in Crop Production, Ed. Paparizas, D.C., Osmun Publishers, Totowa, N.J., USA, pp. 129-141 (1981).
- Ellar, D.J., Knowles, B.H., Drobniowski, S.A. and Haider, M.Z., in "Fundamental and Applied aspects of Invertebrate Pathology". Ed. Samson, R.A., Vlcek, J.M. and Peters, D. (1986) pp. 7-10. Wageningen, Foundation of the fourth International Colloquium of Invertebrate Pathology.
- Engvall and Pesce, Scand. Immunol. Suppl. 7 (1978)
- Finney, Probit Analysis, 3rd Edition, Cambridge University Press (1971)

- Franck, Guilley, Jonard, Richards and Hirth, *Cell* 21, 285-294 (1980)
- French, B.T., Maul, H.N. and Maul, G.G., *Anal.Biochem.* 156, 417-423 (1986)
- Gardner, Howarth, Hahn, Brown-Luedi, Shepard and Messing, *Nucleic Acids Research* 9, 2871-2887 (1981)
- 5 - Gielen, J., De Beuckeleer, M., Seurinck, J., Deboeck, F., De Greve, H., Lemmers, M., Van Montagu, M. and Schell, J., *EMBO J* 3, 835-845 (1984).
- Goldberg, R.B., *Science* 240, 1460-1467 (1988)
- Höfte, H., De Greve, H., Seurinck, J., Jansens, S., Mahillon, J., Ampe, Vandekerckhove, J., Vanderbruggen, H., Van Montagu, M., Zabeau, M. and Vaeck, M., *Eur. J. Biochem.* 161, 273-280 (1986)
- 10 - Höfte, H., Seurinck, J., Van Houtven A. and Vaeck, M., *Nucleic Acids Research* 15, 7183 (1987)
- Höfte, H., Dissertation thesis at the State University of Ghent, Belgium (1988).
- Höfte, H., Van Rie, J., Jansens, S., Van Houtven, A., Verbruggen, H. and Vaeck, M., *Applied and Environmental Microbiology* 54, 2010-2017 (1988)
- Hull and Howell, *Virology* 86, 482-493 (1987)
- 15 - Kuhlemeier, Green and Chua, *Ann. Rev. Plant Physiol.* 38, 221-257 (1987)
- Laemmli V., *Nature* 227, 680-685 (1970)
- Lambert, B., Leyns, F., Van Rooyen, L., Gosselé, F., Papon, Y. and Swings, J. *Applied and Environmental Microbiology* 53, 1866-1871 (1987).
- Mahillon, J. and Delcour, J., *J. Microbiol. Methods* 3, 69-73 (1984)
- 20 - Maxam, A.M. and Gilbert, W., *Methods in Enzymol.* 65, 499-560 (1980).
- Odell, J.T., Nagy, J., and Chua, N., *Nature* 313, 810-812 (1985).
- Peferoen, M. in *Methods in Molecular Biology*, vol. 3 : New Protein Techniques, p. 395-402, Ed. John M. Walker, Humana Press (1988).
- Reiss, B., Sprengel, R., Will, H. and Schaller, H., *Gene* 30, 217-223 (1984)
- 25 - Sneath, P., Mair, N., Sharpe, M. and Holt, J., (1986) in *Bergey's Manual of Systematic Bacteriology*, Vol. 2, pp. 1104-1139. Eds. Williams and Wilkins, Baltimore, London.
- Sutherland, M.W. and Skerritt, J.M., *Electrophoresis* 7, 401-406 (1986)
- Vaeck, M., Reynaerts, A., Höfte, H., Jansens, S., De Beuckeleer, M., Dean, C., Zabeau, M., Van Montagu, M. and Leemans, J., *Nature* 327, 33-37 (1987).
- 30 - Velten, J., Velten, L., Hain, R. and Schell, J., *EMBO J* 3, 2723-2730 (1984).
- Velten, J. and Schell, J. *Nucleic Acids Research* 13, 6981-6998 (1985)
- Yannisch-Perron, C., Vierra, J. and Messing, J., *Gene* 33, 103-119 (1985).

### 35 Claims

1. The BtPGSI208 strain or the BtPGSI245 strain.
2. The BtPGSI208 or BtPGSI245 crystals, crystal proteins, protoxin or toxin.
3. The btPGSI208 or btPGSI245 gene, the insecticidally effective btPGSI208 or btPGSI245 gene part,
- 40 the truncated btPGSI208 or btPGSI245 gene, the btPGSI208 or btPGSI245 chimaeric gene or a hybrid thereof with a selectable marker gene, such as the neo gene.
4. An insecticidal composition, particularly against Coleoptera, which comprises an active ingredient selected from the group consisting of: the BtPGSI208 or BtPGSI245 strain, crystals, crystal proteins, protoxin and toxin and insecticidally effective portions of the BtPGSI208 or BtPGSI245 protoxin.
- 45 5. A transformed microorganism, particularly *E. coli*, characterized by the gene, the gene part, the truncated gene, the chimaeric gene or the hybrid of claim 3.
6. A transformed plant cell, characterized by the insecticidally effective btPGSI208 or btPGSI245 gene part, the truncated btPGSI208 or btPGSI245 gene, the btPGSI208 or btPGSI245 chimaeric gene, or a hybrid thereof with a selectable marker gene, such as the neo gene.
- 50 7. A plant or a seed thereof containing the plant cell of claim 6.
8. A plant genome containing, integrated therein, the gene part, the truncated gene or the chimaeric gene of claim 6.
9. A plant tissue, the cells of which have the plant genome of claim 8.
10. A process for rendering a plant resistant to Coleoptera characterized by: providing the plant with the
- 55 transformed cell of claim 6.
11. In a process for producing plants and reproduction material, such as seeds, of said plants including a heterologous genetic material stably integrated in the genome thereof and capable of being expressed therein in the form of a protein toxic to insects, comprising the non-biological steps of: a) producing

transformed plants cells or plant tissue including said heterologous genetic material from starting plant cells or plant tissue not expressing said protein, b) producing regenerated plants or reproduction material of said plants or both from said transformed plant cells or plant tissue including said heterologous genetic material, and c) optionally, biologically replicating said regenerated plants or reproduction material or both; wherein  
5 said step of producing said transformed plant cells or plant tissue including said heterologous genetic material is characterized by transforming said starting plant cells or plant tissue with the gene part, the truncated gene or the hybrid of claim 6 as well as regulatory elements which are capable of enabling the expression of the gene part, the truncated gene or the hybrid in said plant cells or plant tissue, to cause the stable integration of the gene part, the truncated gene or the hybrid in transformed plant cells or plant  
10 tissue, as well as in said plants and reproduction material produced therefrom throughout generations.

12. A process for controlling an insect pest, especially, Coleoptera, particularly Leptinotarsa decemlineata, Agelastica alni, Diabrotica luteola, Haltica tombacina Anthonomus grandis, Tenebrio molitor and Triboleum castaneum, characterized by contacting the pest with the insecticidal composition of claim 4.

15

20

25

30

35

40

45

50

55

EP 0 382 990 A1

10	20	30	40	50	60	70
TTATCTACAT TTAATCATCT CCATTATAAA TATAATATCT AACACATTG TTGCAAGAGA ATTAATACTA						
80	90	100	110	120	130	140
CTTTGATATT TTTAATATAC TTAACCTAAT GTATTGTTAA GTTAATATAG AATATACCT ATATTAACAA						
150	160	170	180	190	200	210
GGAATTTATT AAAATAATT TTGTATACTT TTCATTGTAA TAACATGATT TTTAAACAA AAAAGTGTAT						
220	230	240	250	260	270	280
AAACAACCTA TCAGGAAGGG GGGGATGCGC AAAGAATAAA AAGAGAATGC TTATAATGTT CAATGGTTTT						
290	300	310	320	330	340	
ATAGGAAGGC ATTTTATCAG GTAGAAAGTT ATGTATTATG ATAAGATGG GAGGAAGAAA A ATG						>
						MET
350	359	368	377	386	395	
AAT CCA AAC AAT CGA AGT GAA TAT GAT ACG ATA AAG GTT ACA CCT AAC AGT GAA						
Asn Pro Asn Asn Arg Ser Glu Tyr Asp Thr Ile Lys Val Thr Pro Asn Ser Glu						
404	413	422	431	440	449	
TTG CCA ACT AAC CAT AAT CAA TAT CCT TTA GCT GAC AAT CCA AAT TCG ACA CTA						
Leu Pro Thr Asn His Asn Gln Tyr Pro Leu Ala Asp Asn Pro Asn Ser Thr Leu						
458	467	476	485	494	503	
GAA GAA TTA AAT TAT AAA GAA TTT TTA AGA ATG ACT GCA GAC AAT TCT ACG GAA						
Glu Glu Leu Asn Tyr Lys Glu Phe Leu Arg MET Thr Ala Asp Asn Ser Thr Glu						
512	521	530	539	548	557	
GTG CTA GAC AGC TCT ACA GTA AAA GAT GCA GTT GGG ACA GGA ATT TCT GTT GTA						
Val Leu Asp Ser Ser Thr Val Lys Asp Ala Val Gly Thr Gly Ile Ser Val Val						
566	575	584	593	602	611	
GGA CAG ATT TTA GGT GTT GTA GGG GTT CCA TTT GCT GGG GCG CTC ACT TCA TTT						
Gly Gln Ile Leu Gly Val Val Gly Val Pro Phe Ala Gly Ala Leu Thr Ser Phe						
620	629	638	647	656	665	
TAT CAA TCA TTT CTT AAC GCT ATA TGG CCA AGT GAT GCT GAC CCA TGG AAG GCT						
Tyr Gln Ser Phe Leu Asn Ala Ile Trp Pro Ser Asp Ala Asp Pro Trp Lys Ala						
674	683	692	701	710	719	
TTT ATG GCA CAA GTG GAA GTA CTG ATA GAT AAG AAA ATA GAG GAG TAT GCT AAA						
Phe MET Ala Gln Val Glu Val Leu Ile Asp Lys Lys Ile Glu Glu Tyr Ala Lys						

FIGURE 1

728	737	746	755	764	773
AGT AAA GCT CTT GCA GAG TTA CAG GGT CTT CAA AAT AAT TTT GAA GAT TAT GTA					
Ser Lys Ala Leu Ala Glu Leu Gln Gly Leu Gln Asn Asn Phe Glu Asp Tyr Val					
782	791	800	809	818	827
AAT GCG TTG GAT TCC TGG AAG AAA GCG CCT GTA AAT TTA CGA AGT CGA AGA AGC					
Asn Ala Leu Asp Ser Trp Lys Lys Ala Pro Val Asn Leu Arg Ser Arg Arg Ser					
836	845	854	863	872	881
CAA GAT CGA ATA AGA GAA CTT TTT TCT CAA GCA GAA AGC CAT TTT CGT AAT TCC					
Gln Asp Arg Ile Arg Glu Leu Phe Ser Gln Ala Glu Ser His Phe Arg Asn Ser					
890	899	908	917	926	935
ATG CCG TCA TTT GCG GTT TCC AAA TTC GAA GTT CTG TTT CTA CCA ACA TAT GCA					
MET Pro Ser Phe Ala Val Ser Lys Phe Glu Val Leu Phe Leu Pro Thr Tyr Ala					
944	953	962	971	980	989
CAA GCT GCA AAT ACA CAT TTA TTG CTA TTA AAA GAT GCT CAA GTT TTT GGA GAA					
Gln Ala Ala Asn Thr His Leu Leu Leu Leu Lys Asp Ala Gln Val Phe Gly Glu					
998	1007	1016	1025	1034	1043
GAA TGG GGA TAT TCT TCA GAA GAT ATT GCT GAA TTT TAT CAA AGA CAA TTA AAA					
Glu Trp Gly Tyr Ser Ser Glu Asp Ile Ala Glu Phe Tyr Gln Arg Gln Leu Lys					
1052	1061	1070	1079	1088	1097
CTT ACG CAA CAA TAC ACT GAC CAT TGT GTC AAT TGG TAT AAT GTT GGA TTA AAT					
Leu Thr Gln Gln Tyr Thr Asp His Cys Val Asn Trp Tyr Asn Val Gly Leu Asn					
1106	1115	1124	1133	1142	1151
AGT TTA AGA GGT TCA ACT TAT GAT GCA TGG GTC AAA TTT AAC CGT TTT CCG AGA					
Ser Leu Arg Gly Ser Thr Tyr Asp Ala Trp Val Lys Phe Asn Arg Phe Arg Arg					
1160	1169	1178	1187	1196	1205
GAA ATG ACA TTA ACT GTA TTA GAT CTA ATT GTA TTA TTC CCA TTT TAT GAT GTT					
Glu MET Thr Leu Thr Val Leu Asp Leu Ile Val Leu Phe Pro Phe Tyr Asp Val					
1214	1223	1232	1241	1250	1259
CGG TTA TAC TCA AAA GGA GTT AAA ACA GAA CTA ACA AGA GAC ATT TTT ACA GAT					
Arg Leu Tyr Ser Lys Gly Val Lys Thr Glu Leu Thr Arg Asp Ile Phe Thr Asp					
1268	1277	1286	1295	1304	1313
CCA ATT TTT ACA CTC AAT GCT CTT CAA GAG TAT GGA CCA ACT TTT TCG AGT ATA					
Pro Ile Phe Thr Leu Asn Ala Leu Gln Glu Tyr Gly Pro Thr Phe Ser Ser Ile					
1322	1331	1340	1349	1358	1367
GAA AAC TCT ATT CGA AAA CCT CAT TTA TTT GAT TAT TTG CGT GGG ATT GAA TTT					
Glu Asn Ser Ile Arg Lys Pro His Leu Phe Asp Tyr Leu Arg Gly Ile Glu Phe					

Figure 1 (cont. 1)

EP 0 382 990 A1

1376	1385	1394	1403	1412	1421
CAT ACG CGT CTT CGA CCT GGT TAC TCT GGG AAA GAT TCT TTC AAT TAT TGG TCT					
His Thr Arg Leu Arg Pro Gly Tyr Ser Gly Lys Asp Ser Phe Asn Tyr Trp Ser					
1430	1439	1448	1457	1466	1475
GGT AAT TAT GTA GAA ACT AGA CCT AGT ATA GGA TCT AAT GAT ACA ATC ACT TCC					
Gly Asn Tyr Val Glu Thr Arg Pro Ser Ile Gly Ser Asn Asp Thr Ile Thr Ser					
1484	1493	1502	1511	1520	1529
CCA TTT TAT GGA GAT AAA TCT ATT GAA CCT ATA CAA AAG CTA AGC TTT GAT GGA					
Pro Phe Tyr Gly Asp Lys Ser Ile Glu Pro Ile Gln Lys Leu Ser Phe Asp Gly					
1538	1547	1556	1565	1574	1583
CAA AAA GTT TAT CGA ACT ATA GCT AAT ACA GAC ATA GCG GCT TTT CCG GAT GGC					
Gln Lys Val Tyr Arg Thr Ile Ala Asn Thr Asp Ile Ala Ala Phe Pro Asp Gly					
1592	1601	1610	1619	1628	1637
AAG ATA TAT TTT GGT GTT ACG AAA GTT GAT TTT AGT CAA TAT GAT GAT CAA AAA					
Lys Ile Tyr Phe Gly Val Thr Lys Val Asp Phe Ser Gln Tyr Asp Asp Gln Lys					
1646	1655	1664	1673	1682	1691
AAT GAA ACT AGT ACA CAA ACA TAT GAT TCA AAA AGA TAC AAT GGC TAT TTA GGT					
Asn Glu Thr Ser Thr Gln Thr Tyr Asp Ser Lys Arg Tyr Asn Gly Tyr Leu Gly					
1700	1709	1718	1727	1736	1745
GCA CAG GAT TCT ATC GAC CAA TTA CCA CCA GAA ACA ACA GAT GAA CCA CTT GAA					
Ala Gln Asp Ser Ile Asp Gln Leu Pro Pro Glu Thr Thr Asp Glu Pro Leu Glu					
1754	1763	1772	1781	1790	1799
AAG GCA TAT AGT CAT CAG CTT AAT TAC GCA GAA TGT TTC TTA ATG CAG GAC CGT					
Lys Ala Tyr Ser His Gln Leu Asn Tyr Ala Glu Cys Phe Leu MET Gln Asp Arg					
1808	1817	1826	1835	1844	1853
CGT GGA ACA ATT CCA TTT TTT ACT TGG ACA CAT AGA AGT GTA GAC TTT TTT AAT					
Arg Gly Thr Ile Pro Phe Phe Thr Trp Thr His Arg Ser Val Asp Phe Phe Asn					
1862	1871	1880	1889	1898	1907
ACA ATT GAT GCT GAA AAA ATT ACT CAA CTT CCA GTA GTG AAA GCA TAT GCC TTG					
Thr Ile Asp Ala Glu Lys Ile Thr Gln Leu Pro Val Val Lys Ala Tyr Ala Leu					
1916	1925	1934	1943	1952	1961
TCT TCA GGC GCT TCC ATT ATT GAA GGT CCA GGA TTC ACA GGA GGA AAT TTA CTA					
Ser Ser Gly Ala Ser Ile Ile Glu Gly Pro Gly Phe Thr Gly Gly Asn Leu Leu					
1970	1979	1988	1997	2006	2015
TTC CTA AAA GAA TCT AGT AAT TCA ATT GCT AAA TTT AAA GTT ACC TTA AAT TCA					
Phe Leu Lys Glu Ser Ser Asn Ser Ile Ala Lys Phe Lys Val Thr Leu Asn Ser					

Figure 1 (cont. 2)

EP 0 382 990 A1

2024	2033	2042	2051	2060	2069	
GCA GCG TTG TTA CAA CGA TAT CCG GTA AGA ATA CGC TAT GCT TCA ACC ACT AAC						
Ala Ala Leu Leu Gln Arg Tyr Arg Val Arg Ile Arg Tyr Ala Ser Thr Thr Asn						
2078	2087	2096	2105	2114	2123	
CTA CGA CTT TTC GTG CAA AAT TCA AAC AAT GAT TTT CTT GTC ATC TAC ATT AAT						
Leu Arg Leu Phe Val Gln Asn Ser Asn Asn Asp Phe Leu Val Ile Tyr Ile Asn						
2132	2141	2150	2159	2168	2177	
AAA ACT ATG AAT ATA GAT GGT GAT TTA ACA TAT CAA ACA TTT GAT TTC GCA ACT						
Lys Thr MET Asn Ile Asp Gly Asp Leu Thr Tyr Gln Thr Phe Asp Phe Ala Thr						
2186	2195	2204	2213	2222	2231	
AGT AAT TCT AAT ATG GGA TTC TCT GGT GAT ACA AAT GAC TTT ATA ATA GGA GCA						
Ser Asn Ser Asn MET Gly Phe Ser Gly Asp Thr Asn Asp Phe Ile Ile Gly Ala						
2240	2249	2258	2267	2276	2285	
GAA TCT TTC GTT TCT AAT GAA AAA ATC TAT ATA GAT AAG ATA GAA TTT ATC CCA						
Glu Ser Phe Val Ser Asn Glu Lys Ile Tyr Ile Asp Lys Ile Glu Phe Ile Pro						
2294	2307	2317	2327	2337	2347	2357
GTA CAA TAG CAAGTGAATT TTGGAATATA GGGCGATGGT CAAAATGAAA GGATAAGAAG GTGAATTTTG						
Val Gln						
2367	2377	2387	2397	2407	2417	
ATGGTTAGGA AAGATTCTTT TAACAAAAGC AACATGGAAA AGTATACAGT ACAAATGGGT ACCGAGCT						

Figure 1 (cont. 3)

Figure 2.

10	20	30	40	50	60	70
TTTGGATTGT GAGCATGTAC AGGTTTGTGA TTACAAGCA AAACCAATCT GCGAAGATTG TTGTCAATTT						
80	90	100	110	120	130	140
ATAAAGGTAA CAGGATATTT TCAATTTGT ACCGATTAAA TAAAAATAT TTAGATTAACT ACTGTTGTTT						
150	160	170	180	189	198	
TTTACAACCTA TCCGTATGGA CAAATTTAAT AAGGAGTGAA AAT ATG AAT TTA AAT AAT TTA						
MET Asn Leu Asn Asn Leu						
207	216	225	234	242	252	
GAT GGA TAT GAA GAT AGT AAT AGA ACA TTA AAT AAT TCT CTC AAT TAT CCT ACT						
Asp Gly Tyr Glu Asp Ser Asn Arg Thr Leu Asn Asn Ser Leu Asn Tyr Pro Thr						
261	270	279	288	297	306	
CAA AAA GCA TTA TCA CCA TCA TTA AAG AAT ATG AAC TAC CAG GAT TTT TTA TCT						
Gln Lys Ala Leu Ser Pro Ser Leu Lys Asn MET Asn Tyr Gln Asp Phe Leu Ser						
315	324	333	342	351	360	
ATA ACT GAG AGG GAA CAA CCT GAA GCA CTC GCT AGT GGT AAT ACA GCT ATT AAT						
Ile Thr Glu Arg Glu Gln Pro Glu Ala Leu Ala Ser Gly Asn Thr Ala Ile Asn						
369	378	387	396	405	414	
ACT GTA GTT AGT GTT ACG GGG GCT ACA CTA AGT GCG TTA GGT GTC CCA GGT GCA						
Thr Val Val Ser Val Thr Gly Ala Thr Leu Ser Ala Leu Gly Val Pro Gly Ala						
423	432	441	450	459	468	
AGT TTT ATC ACT AAC TTT TAC CTG AAA ATT GCA GGC CTT TTA TGG CCA GAA AAT						
Ser Phe Ile Thr Asn Phe Tyr Leu Lys Ile Ala Gly Leu Leu Trp Pro Glu Asn						
477	486	495	504	513	522	
GGA AAA ATT TGG GAT GAA TTT ATG ACA GAA GTA GAA GCA CTT ATT GAT CAA AAA						
Gly Lys Ile Trp Asp Glu Phe MET Thr Glu Val Glu Ala Leu Ile Asp Gln Lys						
531	540	549	558	567	576	
ATA GAA GAA TAT GTA AGA AAT AAA GCG ATT GCA GAA TTA GAT GGA TTA GGA TCA						
Ile Glu Glu Tyr Val Arg Asn Lys Ala Ile Ala Glu Leu Asp Gly Leu Gly Ser						
585	594	603	612	621	630	
GCC TTA GAT AAA TAT CAA AAA GCA CTT GCA GAT TGG CTG GGC AAA CAA GAT GAT						
Ala Leu Asp Lys Tyr Gln Lys Ala Leu Ala Asp Trp Leu Gly Lys Gln Asp Asp						
639	648	657	666	675	684	
CCA GAA GCT ATA CTT TCT GTG GCA ACT GAA TTT CGT ATA ATA GAT TCT CTT TTT						
Pro Glu Ala Ile Leu Ser Val Ala Thr Glu Phe Arg Ile Ile Asp Ser Leu Phe						

Figure 2 (cont. 1)

693	702	711	720	729	738
GAA TTT AGT ATG CCT TCA TTT AAG GTT ACT GGA TAT GAA ATA CCA TTA CTA ACA					
Glu Phe Ser MET Pro Ser Phe Lys Val Thr Gly Tyr Glu Ile Pro Leu Leu Thr					
747	756	765	774	783	792
GTT TAC GCA CAA GCG GCA AAC CTT CAT CTA GCT TTA TTA AGA GAT TCT ACT CTT					
Val Tyr Ala Gln Ala Ala Asn Leu His Leu Ala Leu Leu Arg Asp Ser Thr Leu					
801	810	819	828	837	846
TAT GGA GAT AAA TGG GGA TTC ACT CAG AAC AAC ATT GAG GAA AAT TAT AAT CGT					
Tyr Gly Asp Lys Trp Gly Phe Thr Gln Asn Asn Ile Glu Glu Asn Tyr Asn Arg					
855	864	873	882	891	900
CAA AAG AAA CCG ATT TCT GAA TAT TCA GAC CAT TGC ACC AAG TGG TAT AAT AGT					
Gln Lys Lys Arg Ile Ser Glu Tyr Ser Asp His Cys Thr Lys Trp Tyr Asn Ser					
909	918	927	936	945	954
GGT CTT AGC AGA TTG AAC GGT TCC ACT TAT GAA CAA TGG ATA AAT TAT AAT CGT					
Gly Leu Ser Arg Leu Asn Gly Ser Thr Tyr Glu Gln Trp Ile Asn Tyr Asn Arg					
963	972	981	990	999	1008
TTT CGT AGA GAA ATG ATA TTA ATG GCA TTA GAT CTT GTC GCT GTA TTT CCT TTT					
Phe Arg Arg Glu MET Ile Leu MET Ala Leu Asp Leu Val Ala Val Phe Pro Phe					
1017	1026	1035	1044	1053	1062
CAT GAC CCT CGA AGG TAT TCA ATG GAA ACA AGT ACG CAG TTA ACG AGA GAA GTG					
His Asp Pro Arg Arg Tyr Ser MET Glu Thr Ser Thr Gln Leu Thr Arg Glu Val					
1071	1080	1089	1098	1107	1116
TAT ACC GAT CCA GTT AGC TTG TCA ATT AGC AAT CCA GAT ATA GGT CCA AGT TTT					
Tyr Thr Asp Pro Val Ser Leu Ser Ile Ser Asn Pro Asp Ile Gly Pro Ser Phe					
1125	1134	1143	1152	1161	1170
TCT CAG ATG GAA AAT ACT GCA ATT AGA ACA CCA CAC CTT GTT GAT TAT TTA GAT					
Ser Gln MET Glu Asn Thr Ala Ile Arg Thr Pro His Leu Val Asp Tyr Leu Asp					
1179	1188	1197	1206	1215	1224
GAG CTT TAT ATA TAT ACA TCA AAA TAT AAA GCA TTT TCA CAT GAG ATT CAA CCA					
Glu Leu Tyr Ile Tyr Thr Ser Lys Tyr Lys Ala Phe Ser His Glu Ile Gln Pro					
1233	1242	1251	1260	1269	1278
GAC CTA TTT TAT TGG AGT GCA CAT AAG GTT AGC TTT AAA AAA TCG GAG CAA TCC					
Asp Leu Phe Tyr Trp Ser Ala His Lys Val Ser Phe Lys Lys Ser Glu Gln Ser					
1287	1296	1305	1314	1323	1332
AAT TTA TAT ACA ACA GGC ATA TAT GGT AAA ACA AGT GGA TAT ATT TCA TCA GGG					
Asn Leu Tyr Thr Thr Gly Ile Tyr Gly Lys Thr Ser Gly Tyr Ile Ser Ser Gly					

Figure 2  
(cont. 2)

1341	1350	1359	1368	1377	1386
GCA TAT TCA TTT CAT GGG AAT GAT ATC TAT AGA ACA TTA GCA GCT CCA TCA GTT					
Ala Tyr Ser Phe His Gly Asn Asp Ile Tyr Arg Thr Leu Ala Ala Pro Ser Val					
1395	1404	1413	1422	1431	1440
GTA GTT TAT CCG TAT ACT CAG AAT TAT GGT GTC GAG CAA GTT GAG TT TAC GGT					
Val Val Tyr Pro Tyr Thr Gln Asn Tyr Gly Val Glu Gln Val Glu Phe Tyr Gly					
1449	1458	1467	1476	1485	1494
GTA AAA GGG CAT GTA CAT TAT AGA GGA GAT AAC AAA TAT GAT CTG ACG TAT GAT					
Val Lys Gly His Val His Tyr Arg Gly Asp Asn Lys Tyr Asp Leu Thr Tyr Asp					
1503	1512	1521	1530	1539	1548
TCT ATT GAT CAA TTA CCC CCA GAC GGA GAA CCA ATA CAC GAA AAA TAC ACT CAT					
Ser Ile Asp Gln Leu Pro Pro Asp Gly Glu Pro Ile His Glu Lys Tyr Thr His					
1557	1566	1575	1584	1593	1602
CGA TTA TGT CAT GCT ACA GCT ATA TTT AAA TCA ACT CCG GAT TAT GAT AAT GCT					
Arg Leu Cys His Ala Thr Ala Ile Phe Lys Ser Thr Pro Asp Tyr Asp Asn Ala					
1611	1620	1629	1638	1647	1656
ACT ATC CCG ATC TTT TCT TGG ACG CAT AGA AGT GCG GAG TAT TAC AAT AGA ATC					
Thr Ile Pro Ile Phe Ser Trp Thr His Arg Ser Ala Glu Tyr Tyr Asn Arg Ile					
1665	1674	1683	1692	1701	1710
TAT CCA AAC AAA ATC ACA AAA ATT CCA GCT GTA AAA ATG TAT AAA CTG GAT GAT					
Tyr Pro Asn Lys Ile Thr Lys Ile Pro Ala Val Lys MET Tyr Lys Leu Asp Asp					
1719	1728	1737	1746	1755	1764
CCA TCT ACA GTT GTC AAA GGG CCT GGA TTT ACA GGT GGA GAT TTA GTT AAG AGA					
Pro Ser Thr Val Val Lys Gly Pro Gly Phe Thr Gly Gly Asp Leu Val Lys Arg					
1773	1782	1791	1800	1809	1818
GGG AGT ACT GGT TAT ATA GGA GAT ATA AAG GCT ACC GTA AAC TCT CCA CTT TCT					
Gly Ser Thr Gly Tyr Ile Gly Asp Ile Lys Ala Thr Val Asn Ser Pro Leu Ser					
1827	1836	1845	1854	1863	1872
CAA AAA TAT CGT GTT AGA GTT CGA TAC GCT ACT AAT GTT TCT GGA CAG TTC AAC					
Gln Lys Tyr Arg Val Arg Val Arg Tyr Ala Thr Asn Val Ser Gly Gln Phe Asn					
1881	1890	1899	1908	1917	1926
GTG TAT ATT AAT GAT AAA ATA ACG CTT CAA ACA AAG TTT CAA AAT ACT GTA GAA					
Val Tyr Ile Asn Asp Lys Ile Thr Leu Gln Thr Lys Phe Gln Asn Thr Val Glu					
1935	1944	1953	1962	1971	1980
ACA ATA GGT GAA GGA AAA GAT TTA ACC TAT GAT TCA TTT GGA TAT ATA GAA TAT					
Thr Ile Gly Glu Gly Lys Asp Leu Thr Tyr Gly Ser Phe Gly Tyr Ile Glu Tyr					
1989	1998	2007	2016	2025	2034
TCT ACG ACC ATT CAA TTT CCG GAT GAG CAT CCA AAA ATC ACT CTT CAT TTA AGC					
Ser Thr Thr Ile Gln Phe Pro Asp Glu His Pro Lys Ile Thr Leu His Leu Ser					

Figure 2  
(cont. 3)

2043	2052	2061	2070	2079	2088
GAT TTG AGT AAC AAT TCA TCA TTT TAT GTA GAT TCA ATC GAA TTT ATC CCT GTA					
Asp Leu Ser Asn Asn Ser Ser Phe Tyr Val Asp Ser Ile Glu Phe Ile Pro Val					
2097	2106	2115	2124	2133	2142
GAT GTA AAT TAT GCT GAA AAA GAA AAA CTA GAA AAA GCA CAG AAA GCC GTG AAT					
Asp Val Asn Tyr Ala Glu Lys Glu Lys Leu Glu Lys Ala Gln Lys Ala Val Asn					
2151	2160	2169	2178	2187	2196
ACC TTG TTT ACA GAG GGA AGA AAT GCA CTC CAA AAA GAC GTG ACA GAT TAT AAA					
Thr Leu Phe Thr Glu Gly Arg Asn Ala Leu Gln Lys Asp Val Thr Asp Tyr Lys					
2205	2214	2223	2232	2241	2250
GTG GAC CAG GTT TCA ATT TTA GTG GAT TGT ATA TCA GGG GAT TTA TAT CCC AAT					
Val Asp Gln Val Ser Ile Leu Val Asp Cys Ile Ser Gly Asp Leu Tyr Pro Asn					
2259	2268	2277	2286	2295	2304
GAG AAA CGC GAA CTA CAA AAT CTA GTC AAA TAC GCA AAA CGT TTG AGC TAT TCC					
Glu Lys Arg Glu Leu Gln Asn Leu Val Lys Tyr Ala Lys Arg Leu Ser Tyr Ser					
2313	2322	2331	2340	2349	2358
CGT AAT TTA CTT CTA GAT CCA ACA TTC GAT TCT ATT AAT TCA TCT GAG GAG AAT					
Arg Asn Leu Leu Leu Asp Pro Thr Phe Asp Ser Ile Asn Ser Ser Glu Glu Asn					
2367	2376	2385	2394	2403	2412
GGT TGG TAT GGA AGT AAT GGT ATT GTG ATT GGA AAT GGG GAT TTT GTA TTC AAA					
Gly Trp Tyr Gly Ser Asn Gly Ile Val Ile Gly Asn Gly Asp Phe Val Phe Lys					
2421	2430	2439	2448	2457	2466
GGT AAC TAT TTA ATT TTT TCA GGT ACC AAT GAT ACA CAA TAT CCA ACA TAT CTC					
Gly Asn Tyr Leu Ile Phe Ser Gly Thr Asn Asp Thr Gln Tyr Pro Thr Tyr Leu					
2475	2484	2493	2502	2511	2520
TAC CAA AAA ATA GAT GAA TCC AAA CTC AAA GAA TAT ACA CGC TAT AAA CTG AAA					
Tyr Gln Lys Ile Asp Glu Ser Lys Leu Lys Glu Tyr Thr Arg Tyr Lys Leu Lys					
2529	2538	2547	2556	2565	2574
GGT TTT ATC GAA AGT AGT CAG GAT TTA GAA GCT TAT GTG ATT CGC TAT GAT GCA					
Gly Phe Ile Glu Ser Ser Gln Asp Leu Glu Ala Tyr Val Ile Arg Tyr Asp Ala					
2583	2592	2601	2610	2619	2628
AAA CAT AGA ACA TTG GAT GTT TCT GAT AAT CTA TTA CCA GAT ATT CTC CCT GAG					
Lys His Arg Thr Leu Asp Val Ser Asp Asn Leu Leu Pro Asp Ile Leu Pro Glu					
2637	2646	2655	2664	2673	2682
AAT ACA TGT GGA GAA CCA AAT CGC TGC GCG GCA CAA CAA TAC CTG GAT GAA AAT					
Asn Thr Cys Gly Glu Pro Asn Arg Cys Ala Ala Gln Gln Tyr Leu Asp Glu Asn					
2691	2700	2709	2718	2727	2736
CCA AGT CCA GAA TGT AGT TCG ATG CAA GAT GGA ATT TTG TCT GAT TCG CAT TCA					
Pro Ser Pro Glu Cys Ser Ser MET Gln Asp Gly Ile Leu Ser Asp Ser His Ser					


Figure 2  
(cont. 4)

2745	2754	2763	2772	2781	2790
TTT TCT CTT AAT ATA GAT ACA GGT TCT ATC AAT CAC AAT GAG AAT TTA GGA ATT					
Phe Ser Leu Asn Ile Asp Thr Gly Ser Ile Asn His Asn Glu Asn Leu Gly Ile					
2799	2808	2817	2826	2835	2844
TGG GTG TTG TTT AAA ATT TCG ACA TTA GAA GGA TAT GCG AAA TTT GGA AAT CTA					
Trp Val Leu Phe Lys Ile Ser Thr Leu Glu Gly Tyr Ala Lys Phe Gly Asn Leu					
2853	2862	2871	2880	2889	2898
GAA GTG ATT GAA GAT GGC CCA GTT ATT GGA GAA GCA TTA GCC CGT GTG AAA CGC					
Glu Val Ile Glu Asp Gly Pro Val Ile Gly Glu Ala Leu Ala Arg Val Lys Arg					
2907	2916	2925	2934	2943	2952
CAA GAA ACG AAG TGG AGA AAC AAG TTA GCC CAA CTG ACA ACG GAA ACA CAA GCG					
Gln Glu Thr Lys Trp Arg Asn Lys Leu Ala Gln Leu Thr Thr Glu Thr Gln Ala					
2961	2970	2979	2988	2997	3006
ATT TAT ACA CGA GCA AAA CAA GCG CTG GAT AAT CTT TTT GCG AAT GCA CAA GAC					
Ile Tyr Thr Arg Ala Lys Gln Ala Leu Asp Asn Leu Phe Ala Asn Ala Gln Asp					
3015	3024	3033	3042	3051	3060
TCT CAC TTA AAA AGA GAT GTT ACA TTT GCG GAA ATT GCG GCT GCA AGA AAG ATT					
Ser His Leu Lys Arg Asp Val Thr Phe Ala Glu Ile Ala Ala Ala Arg Lys Ile					
3069	3078	3087	3096	3105	3114
GTC CAA TCA ATA GCG GAA GCG TAT ATG TCA TGG TTA TCT GTT GTT CCA GGT GTA					
Val Gln Ser Ile Arg Glu Ala Tyr MET Ser Trp Leu Ser Val Val Pro Gly Val					
3123	3132	3141	3150	3159	3168
AAT CAC CCT ATT TTT ACA GAG TTA AGT GGG CGA GTA CAA CGA GCA TTT CAA TTA					
Asn His Pro Ile Phe Thr Glu Leu Ser Gly Arg Val Gln Arg Ala Phe Gln Leu					
3177	3186	3195	3204	3213	3222
TAT GAT GTA CGA AAT GTT GTG CGT AAT GGT CGA TTC CTC AAT GGC TTA TCC GAT					
Tyr Asp Val Arg Asn Val Val Arg Asn Gly Arg Phe Leu Asn Gly Leu Ser Asp					
3231	3240	3249	3258	3267	3276
TGG ATT GTA ACA TCT GAC GTA AAG GTA CAA GAA GAA AAT GGG AAT AAC GTA TTA					
Trp Ile Val Thr Ser Asp Val Lys Val Gln Glu Glu Asn Gly Asn Asn Val Leu					
3285	3294	3303	3312	3321	3330
GTT CTT AAC AAT TGG GAT GCA CAA GTA TTA CAA AAC GTA AAA CTC TAT CAA GAC					
Val Leu Asn Asn Trp Asp Ala Gln Val Leu Gln Asn Val Lys Leu Tyr Gln Asp					
3339	3348	3357	3366	3375	3384
CGT GGG TAT ATC TTA CAT GTA ACA GCG GCG AAG ATA GGA ATT GGG GAA GGA TAT					
Arg Gly Tyr Ile Leu His Val Thr Ala Arg Lys Ile Gly Ile Gly Glu Gly Tyr					

Figure 2  
(cont. 5)


3393	3402	3411	3420	3429	3438	
ATA ACG ATT ACG GAT GAA GAA GGG CAT ACA GAT CAA TTG AGA TTT ACT GCA TGT						
Ile Thr Ile Thr Asp Glu Glu Gly His Thr Asp Gln Leu Arg Phe Thr Ala Cys						
3447	3456	3465	3474	3483	3492	
GAA GAG ATT GAT GCA TCT AAT GCG TTT ATA TCC GGT TAT ATT ACA AKA GAA CTG						
Glu Glu Ile Asp Ala Ser Asn Ala Phe Ile Ser Gly Tyr Ile Thr Lys Glu Leu						
3501	3510	3519	3528	3537	3546	
GAA TTC TTC CCA GAT ACA GAG AAA GTG CAT ATA GAA ATA GGC GAA ACA GAA GGA						
Glu Phe Phe Pro Asp Thr Glu Lys Val His Ile Glu Ile Gly Glu Thr Glu Gly						
3555	3564	3573	3582	3591	3600	3610
ATA TTC CTG GTA GAA AGT ATA GAG TTA TTT TTG ATG GAA GAG CTA TGT TAA TAGGGAGATT						
Ile Phe Leu Val Glu Ser Ile Glu Leu Phe Leu MET Glu Glu Leu Cys						
3620	3630	3640	3650	3660	3670	3680
ATTCAACAAA TATTTGTTTG ATTCAAATA AAATAAATG CATACAATCC TCTTTATCAG ACGGTATTC						
3690	3700	3710	3720	3730	3740	3750
TAATAATTAT AAATATAGGT TGAAGTTAA AAAATAAAAA CACGCTATTC CCATTACTAG AAGGAGGGAG						
3760	3770	3780	3790	3800	3810	3820
TAACGTGTTT TTTCATGAGT AAAAAACAA TTAGCTATAT TTATCTATTC TCTATAGAAG AAGCGGATTG						
3830	3840	3850	3860	3870	3880	3890
ATAAGAACCG TAAGTGACAG GAATAGCATT TATATCTTAT AGTGCAAGTC CAATCAATG AAGGATAGTAG						
3900	3910	3920	3930	3940	3950	3960
AGTGACAAAA ACGCTTGAAG TTTTCCAAAA AAGAAATCAA GTACAAATTG AAATTGATAC AACAAATGTT						
3970	3980	3990	4000			
ATTTCCTTAG TAGAACGTAT AGAATTATTA TGTTTGGGAG ATGA						

Total protein pattern of  
sporulated B.t.s by SDS-PAGE



**Figure 3**

Protein blotting of BtS1 and PGSI208  
proteins and trypsinized crystal proteins



**Figure 4a**

Protein blotting of HD110, PGSI245 and BtS1  
solubilized and trypsinized crystal proteins




Figure 4b



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	WO-A-8 808 880 (ECOGEN INCORPORATED) * abstract; page 13, line 25 - page 14, line 29; page 38, line 30 - page 39, line 35; page 41, line 30 - page 42, line 30; figure 8; claims 1-5, 8-14, 17-25, 28-54, 60, 62, 65-67 * ---	1-12	C 12 N 15/32 A 01 N 63/00
D, A	EP-A-0 213 818 (MYCOGEN CORPORATION) * abstract; column 2, lines 5-17; column 3, line 54 - column 4, line 54; column 5, lines 1-37; column 6, lines 1-16; column 6, lines 31-34; examples 2-5; tables A, B; claims * ---	2-5, 12	
A	EP-A-0 289 479 (MONSANTO COMPANY) * whole document * ---	1-12	
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA vol. 84, no. 20, October 1987, pages 7036-7040, Washington, DC, USA; V. SEKAR et al.: "Molecular cloning and characterization of the insecticidal crystal protein gene of <i>Bacillus thuringiensis</i> var. <i>tenebrionis</i> " * whole document * ---	2-5, 12	TECHNICAL FIELDS SEARCHED (Int. Cl.5)  C 12 N 15/32 C 12 N 15/82 A 01 N 63/00 A 01 N 63/02
A	BIOSIS DATABASE abstract no. 87-046633, 1987; W.P. DONOVAN et al.: "Isolation and characterization of EG2158 a new strain of <i>Bacillus-Thuringiensis</i> toxic to coleopteran larvae and nucleotide sequence of the toxin gene" & Molecular & General Genetics 1988, vol. 214, no. 3, pages 365-372 --- -/-	1-5	
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 27-09-1989	Examiner JULIA P.
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document  T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			

EPO FORM 1500 (03.82) (P0401)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,A	EP-A-0 193 259 (PLANT GENETIC SYSTEMS N.V.) * whole document * -----	1-12	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 27-09-1989	Examiner JULIA P.
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (PC401)